Makers Laboratories

Makers Laboratories EBIT per Employee

The EBIT per Employee of Makers Laboratories (506919.BO) as of Oct 18, 2026 is 968,132.23 INR. In the previous year, EBIT per Employee was 249,148.76 INR — a change of 288.58% (higher).

EBIT per Employee

968,132.23INR

YoY

288.58%

Last updated:

EBIT per Employee of Makers Laboratories is 2026 968,132.23 INR. EBIT per Employee of Makers Laboratories was 2025 249,148.76 INR. It decreases by 288.58% higher compared to the previous year.

The Makers Laboratories EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
237,479.34 INR
Jan 1, 2020
93,669.42 INR
Jan 1, 2021
304,066.12 INR
Jan 1, 2022
1.38 M INR
Jan 1, 2023
105,991.74 INR
Jan 1, 2024
-162,239.67 INR
Jan 1, 2025
249,148.76 INR
Jan 1, 2026
968,132.23 INR
The Makers Laboratories EBIT per Employee history
YEAREBIT per EmployeeYoY
968,132.23INR+288.58%
249,148.76INR-253.57%
-162,239.67INR-253.07%
105,991.74INR-92.31%
1.38 MINR+353.24%
304,066.12INR+224.62%
93,669.42INR-60.56%
237,479.34INR-1.61%
241,355.37INR-32.22%
356,107.44INR+26.13%
282,333.14INR+20.38%
234,535.21INR+85.69%
126,306.21INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India, operating within the Health Care sector. The company has a workforce of 121 employees and went public on July 13, 1993. It manufactures and markets pharmaceutical products, focusing on various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). Additionally, Makers Laboratories offers Inspira retail packs, covering categories like acid regulatory, anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics, anti-nauseants, anti-fungal, anti-hypertensives, and other health-related products. The Experia bulk packs division provides bulk pharmaceutical products including amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and similar items. The company's website is https://www.makerslabs.com/. Makers Laboratories Ltd is listed on the Bombay Stock Exchange under the ticker 506919.BO and holds the ISIN INE987A01010. The company operates through the pharmaceuticals segment, emphasizing general health therapeutic areas. It does not disclose specific financial figures or additional details beyond its product lines and operational structure. Makers Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Makers Laboratories stock

EBIT per Employee of Makers Laboratories is 968,132.23 INR in 2026.

EBIT per Employee of Makers Laboratories changed from 249,148.76 INR to 968,132.23 INR, representing a 288.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Makers Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Makers Laboratories

All Key Metrics — Makers Laboratories